突触囊泡糖蛋白2A亚型PET显像用于缺血性卒中神经功能恢复
本研究在大鼠光血栓性脑梗死模型中,从卒中后第3天至第14天腹腔给予沙芬酰胺以减轻神经功能缺损,并用[18F]SynVesT-1 PET/CT与[18F]FDG PET/CT评估梗死体积、突触密度与脑葡萄糖代谢。结果显示沙芬酰胺改善行为学结局,[18F]SynVesT-1 PET可定量突触密度时空动态,且与神经功能恢复的相关性优于[18F]FDG PET。
要点
- 沙芬酰胺治疗改善卒中大鼠行为学结局。
- [18F]SynVesT-1 PET与[18F]FDG PET均能检出卒中损伤,后者损伤区显著更大。
- [18F]SynVesT-1 PET与神经功能恢复的相关性优于[18F]FDG PET。
核心结论
- [18F]SynVesT-1 PET有效定量卒中大鼠模型突触密度的时空动态,与[18F]FDG PET相比在检测卒中损伤和神经功能恢复方面表现不同。
- [18F]SynVesT-1 PET有潜力作为联合[18F]FDG PET评估缺血性卒中的无创生物标志物。
研究设计与样本
- 研究采用Sprague-Dawley大鼠光血栓性脑梗死模型,卒中后第3天至第14天腹腔给予沙芬酰胺以减轻神经功能缺损。
- 采用圆柱试验和前肢放置试验评估神经功能,并用MRI、[18F]SynVesT-1 PET/CT和[18F]FDG PET/CT评估治疗前后梗死体积、突触密度和脑葡萄糖代谢。
- 采用统计参数映射(SPM)和感兴趣区(ROI)分析比较[18F]SynVesT-1与[18F]FDG PET图像,并用死后组织学分析验证PET图像。
主要发现
- 沙芬酰胺治疗改善卒中大鼠行为学结局。
- [18F]SynVesT-1 PET与[18F]FDG PET均检出卒中诱导的损伤,[18F]FDG PET的损伤区显著大于[18F]SynVesT-1 PET。
- 与盐水组相比,沙芬酰胺治疗后[18F]SynVesT-1 PET损伤区放射性示踪剂摄取显著增加,而[18F]FDG PET未见明显变化。
- [18F]SynVesT-1 PET与神经功能恢复的相关性优于[18F]FDG PET。
- 死后分析显示治疗后卒中损伤区神经元数量、突触密度和突触神经可塑性增加,胶质激活减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: [18F]SynVesT-1 is a novel radiopharmaceutical for assessing synaptic density in vivo. This study aims to investigate the potential of [18F]SynVesT-1 positron emission tomography (PET) in evaluating neurological recovery in the rat model of ischemic stroke, and to compare its performance with [18F]FDG PET. METHODS: Sprague-Dawley rats were subjected to photothrombotic cerebral infarction, and safinamide was administered intraperitoneally from day 3 to day 14 post-stroke to alleviate neurological deficits. Cylinder test and forelimb placing test were performed to assess the neurological function. MRI, [18F]SynVesT-1 PET/CT and [18F]FDG PET/CT imaging were used to evaluate infarct volume, synaptic density, and cerebral glucose metabolism pre- and post-treatment. [18F]SynVesT-1 and [18F]FDG PET images were compared using Statistical Parametric Mapping (SPM) and region of interest (ROI)-based analysis. Post-mortem histological analysis was performed to validate PET images. RESULTS: Safinamide treatment improved behavioral outcomes in stroke-damaged rats. Both [18F]SynVesT-1 and [18F]FDG PET detected stroke-induced injury, with the injured region being significantly larger in [18F]FDG PET than in [18F]SynVesT-1 PET. Compared with the saline group, radiotracer uptake in the injured area significantly increased in [18F]SynVesT-1 PET after safinamide treatment, whereas no notable change was observed in [18F]FDG PET. Additionally, [18F]SynVesT-1 PET imaging showed a better correlation with neurological function recovery than [18F]FDG PET. Post-mortem analysis revealed increased neuronal numbers, synaptic density, and synaptic neuroplasticity, as well as decreased glia activation in the stroke-injured area after treatment. CONCLUSION: [18F]SynVesT-1 PET effectively quantified spatiotemporal dynamics of synaptic density in the rat model of stroke, and showed different capabilities in detecting stroke injury and neurological recovery compared with [18F]FDG PET. The utilization of [18F]SynVesT-1 PET holds promise as a potential non-invasive biomarker for evaluating ischemic stroke in conjunction with [18F]FDG PET.
引用
- Luo X, Jin C, Chen H, et al. PET imaging of synaptic vesicle glycoprotein 2 subtype A for neurological recovery in ischemic stroke. Eur J Nucl Med Mol Imaging. 2024. PMID: 39196302. doi:10.1007/s00259-024-06904-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。